nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—Alzheimer's disease	0.388	1	CbGaD
Vandetanib—FLT4—blood vessel—Alzheimer's disease	0.00237	0.0197	CbGeAlD
Vandetanib—RIPK2—blood vessel—Alzheimer's disease	0.00236	0.0196	CbGeAlD
Vandetanib—Bosutinib—LRRK2—Alzheimer's disease	0.0021	0.424	CrCbGaD
Vandetanib—Bosutinib—PTK2B—Alzheimer's disease	0.0021	0.424	CrCbGaD
Vandetanib—TEK—blood vessel—Alzheimer's disease	0.00191	0.0158	CbGeAlD
Vandetanib—SRC—blood vessel—Alzheimer's disease	0.00169	0.0141	CbGeAlD
Vandetanib—EPHA5—forebrain—Alzheimer's disease	0.00162	0.0134	CbGeAlD
Vandetanib—TYRO3—forebrain—Alzheimer's disease	0.00162	0.0134	CbGeAlD
Vandetanib—KDR—blood vessel—Alzheimer's disease	0.00156	0.0129	CbGeAlD
Vandetanib—TYRO3—telencephalon—Alzheimer's disease	0.00149	0.0124	CbGeAlD
Vandetanib—EPHA5—telencephalon—Alzheimer's disease	0.00149	0.0124	CbGeAlD
Vandetanib—FLT4—embryo—Alzheimer's disease	0.00141	0.0117	CbGeAlD
Vandetanib—PDGFRB—blood vessel—Alzheimer's disease	0.00135	0.0112	CbGeAlD
Vandetanib—ERBB3—embryo—Alzheimer's disease	0.00135	0.0112	CbGeAlD
Vandetanib—FGR—embryo—Alzheimer's disease	0.00125	0.0104	CbGeAlD
Vandetanib—RET—embryo—Alzheimer's disease	0.00125	0.0104	CbGeAlD
Vandetanib—FMO1—forebrain—Alzheimer's disease	0.00123	0.0102	CbGeAlD
Vandetanib—ERBB3—forebrain—Alzheimer's disease	0.00119	0.00988	CbGeAlD
Vandetanib—EGFR—telencephalon—Alzheimer's disease	0.00118	0.0098	CbGeAlD
Vandetanib—FYN—embryo—Alzheimer's disease	0.00116	0.00966	CbGeAlD
Vandetanib—VEGFA—telencephalon—Alzheimer's disease	0.00114	0.00947	CbGeAlD
Vandetanib—TEK—embryo—Alzheimer's disease	0.00114	0.00944	CbGeAlD
Vandetanib—EPHA8—nervous system—Alzheimer's disease	0.00114	0.00944	CbGeAlD
Vandetanib—ERBB3—telencephalon—Alzheimer's disease	0.00109	0.00909	CbGeAlD
Vandetanib—EPHA8—central nervous system—Alzheimer's disease	0.00109	0.00908	CbGeAlD
Vandetanib—EPHA8—cerebellum—Alzheimer's disease	0.00107	0.00888	CbGeAlD
Vandetanib—FYN—forebrain—Alzheimer's disease	0.00103	0.00855	CbGeAlD
Vandetanib—MKNK1—telencephalon—Alzheimer's disease	0.00103	0.00853	CbGeAlD
Vandetanib—AXL—telencephalon—Alzheimer's disease	0.00101	0.0084	CbGeAlD
Vandetanib—SRC—embryo—Alzheimer's disease	0.00101	0.00839	CbGeAlD
Vandetanib—MAP4K5—forebrain—Alzheimer's disease	0.00101	0.00835	CbGeAlD
Vandetanib—SLK—telencephalon—Alzheimer's disease	0.000973	0.00808	CbGeAlD
Vandetanib—EPHB6—forebrain—Alzheimer's disease	0.000961	0.00798	CbGeAlD
Vandetanib—EPHA6—nervous system—Alzheimer's disease	0.000947	0.00787	CbGeAlD
Vandetanib—FYN—telencephalon—Alzheimer's disease	0.000946	0.00786	CbGeAlD
Vandetanib—KDR—embryo—Alzheimer's disease	0.000929	0.00772	CbGeAlD
Vandetanib—TEK—telencephalon—Alzheimer's disease	0.000924	0.00768	CbGeAlD
Vandetanib—MAP4K5—telencephalon—Alzheimer's disease	0.000924	0.00768	CbGeAlD
Vandetanib—EPHA6—central nervous system—Alzheimer's disease	0.000912	0.00757	CbGeAlD
Vandetanib—LTK—brain—Alzheimer's disease	0.000906	0.00752	CbGeAlD
Vandetanib—SRC—forebrain—Alzheimer's disease	0.000893	0.00742	CbGeAlD
Vandetanib—EPHB6—telencephalon—Alzheimer's disease	0.000883	0.00734	CbGeAlD
Vandetanib—EPHA5—nervous system—Alzheimer's disease	0.000879	0.0073	CbGeAlD
Vandetanib—TYRO3—nervous system—Alzheimer's disease	0.000879	0.0073	CbGeAlD
Vandetanib—LYN—nervous system—Alzheimer's disease	0.000874	0.00726	CbGeAlD
Vandetanib—EPHA8—brain—Alzheimer's disease	0.000868	0.00721	CbGeAlD
Vandetanib—BMPR1B—nervous system—Alzheimer's disease	0.000861	0.00715	CbGeAlD
Vandetanib—MAP3K19—nervous system—Alzheimer's disease	0.000861	0.00715	CbGeAlD
Vandetanib—YES1—telencephalon—Alzheimer's disease	0.000854	0.00709	CbGeAlD
Vandetanib—TYRO3—central nervous system—Alzheimer's disease	0.000846	0.00703	CbGeAlD
Vandetanib—EPHA5—central nervous system—Alzheimer's disease	0.000846	0.00703	CbGeAlD
Vandetanib—LYN—central nervous system—Alzheimer's disease	0.000842	0.00699	CbGeAlD
Vandetanib—BMPR1B—central nervous system—Alzheimer's disease	0.000829	0.00688	CbGeAlD
Vandetanib—MAP3K19—central nervous system—Alzheimer's disease	0.000829	0.00688	CbGeAlD
Vandetanib—EPHA5—cerebellum—Alzheimer's disease	0.000827	0.00687	CbGeAlD
Vandetanib—TYRO3—cerebellum—Alzheimer's disease	0.000827	0.00687	CbGeAlD
Vandetanib—KDR—forebrain—Alzheimer's disease	0.000822	0.00682	CbGeAlD
Vandetanib—SRC—telencephalon—Alzheimer's disease	0.000821	0.00682	CbGeAlD
Vandetanib—BMPR1B—cerebellum—Alzheimer's disease	0.00081	0.00673	CbGeAlD
Vandetanib—PDGFRB—embryo—Alzheimer's disease	0.000804	0.00668	CbGeAlD
Vandetanib—MAP2K5—telencephalon—Alzheimer's disease	0.000756	0.00628	CbGeAlD
Vandetanib—STK35—nervous system—Alzheimer's disease	0.000732	0.00608	CbGeAlD
Vandetanib—EPHA6—brain—Alzheimer's disease	0.000724	0.00601	CbGeAlD
Vandetanib—ABL1—embryo—Alzheimer's disease	0.000717	0.00595	CbGeAlD
Vandetanib—PLK4—brain—Alzheimer's disease	0.000715	0.00594	CbGeAlD
Vandetanib—STK35—central nervous system—Alzheimer's disease	0.000705	0.00585	CbGeAlD
Vandetanib—FLT3—cerebellum—Alzheimer's disease	0.000703	0.00584	CbGeAlD
Vandetanib—STK35—cerebellum—Alzheimer's disease	0.000689	0.00572	CbGeAlD
Vandetanib—TYRO3—brain—Alzheimer's disease	0.000672	0.00558	CbGeAlD
Vandetanib—EPHA5—brain—Alzheimer's disease	0.000672	0.00558	CbGeAlD
Vandetanib—ABL2—cerebellum—Alzheimer's disease	0.000671	0.00558	CbGeAlD
Vandetanib—FMO1—nervous system—Alzheimer's disease	0.000669	0.00556	CbGeAlD
Vandetanib—LYN—brain—Alzheimer's disease	0.000668	0.00555	CbGeAlD
Vandetanib—IRAK4—nervous system—Alzheimer's disease	0.000659	0.00547	CbGeAlD
Vandetanib—BMPR1B—brain—Alzheimer's disease	0.000658	0.00547	CbGeAlD
Vandetanib—MAP3K19—brain—Alzheimer's disease	0.000658	0.00547	CbGeAlD
Vandetanib—EGFR—cerebellum—Alzheimer's disease	0.000655	0.00544	CbGeAlD
Vandetanib—PDGFRB—telencephalon—Alzheimer's disease	0.000654	0.00543	CbGeAlD
Vandetanib—ERBB3—nervous system—Alzheimer's disease	0.000646	0.00537	CbGeAlD
Vandetanib—FMO1—central nervous system—Alzheimer's disease	0.000645	0.00535	CbGeAlD
Vandetanib—RIPK2—cerebellum—Alzheimer's disease	0.000635	0.00528	CbGeAlD
Vandetanib—IRAK4—central nervous system—Alzheimer's disease	0.000635	0.00527	CbGeAlD
Vandetanib—VEGFA—cerebellum—Alzheimer's disease	0.000633	0.00526	CbGeAlD
Vandetanib—ERBB3—central nervous system—Alzheimer's disease	0.000622	0.00517	CbGeAlD
Vandetanib—IRAK4—cerebellum—Alzheimer's disease	0.00062	0.00515	CbGeAlD
Vandetanib—ERBB3—cerebellum—Alzheimer's disease	0.000608	0.00505	CbGeAlD
Vandetanib—MKNK1—nervous system—Alzheimer's disease	0.000607	0.00504	CbGeAlD
Vandetanib—RET—nervous system—Alzheimer's disease	0.000599	0.00498	CbGeAlD
Vandetanib—FGR—nervous system—Alzheimer's disease	0.000599	0.00498	CbGeAlD
Vandetanib—AXL—nervous system—Alzheimer's disease	0.000597	0.00496	CbGeAlD
Vandetanib—MKNK1—central nervous system—Alzheimer's disease	0.000584	0.00485	CbGeAlD
Vandetanib—ABL1—telencephalon—Alzheimer's disease	0.000583	0.00484	CbGeAlD
Vandetanib—FMO3—nervous system—Alzheimer's disease	0.000579	0.00481	CbGeAlD
Vandetanib—FGR—central nervous system—Alzheimer's disease	0.000577	0.00479	CbGeAlD
Vandetanib—RET—central nervous system—Alzheimer's disease	0.000577	0.00479	CbGeAlD
Vandetanib—AXL—central nervous system—Alzheimer's disease	0.000575	0.00477	CbGeAlD
Vandetanib—MKNK1—cerebellum—Alzheimer's disease	0.000571	0.00474	CbGeAlD
Vandetanib—RET—cerebellum—Alzheimer's disease	0.000564	0.00468	CbGeAlD
Vandetanib—AXL—cerebellum—Alzheimer's disease	0.000562	0.00466	CbGeAlD
Vandetanib—STK35—brain—Alzheimer's disease	0.00056	0.00465	CbGeAlD
Vandetanib—FYN—nervous system—Alzheimer's disease	0.000558	0.00464	CbGeAlD
Vandetanib—FMO3—central nervous system—Alzheimer's disease	0.000557	0.00463	CbGeAlD
Vandetanib—MAP4K5—nervous system—Alzheimer's disease	0.000546	0.00453	CbGeAlD
Vandetanib—TEK—nervous system—Alzheimer's disease	0.000546	0.00453	CbGeAlD
Vandetanib—ABL2—brain—Alzheimer's disease	0.000545	0.00453	CbGeAlD
Vandetanib—SLK—cerebellum—Alzheimer's disease	0.000541	0.00449	CbGeAlD
Vandetanib—FYN—central nervous system—Alzheimer's disease	0.000538	0.00447	CbGeAlD
Vandetanib—EGFR—brain—Alzheimer's disease	0.000532	0.00442	CbGeAlD
Vandetanib—FYN—cerebellum—Alzheimer's disease	0.000526	0.00437	CbGeAlD
Vandetanib—MAP4K5—central nervous system—Alzheimer's disease	0.000525	0.00436	CbGeAlD
Vandetanib—TEK—central nervous system—Alzheimer's disease	0.000525	0.00436	CbGeAlD
Vandetanib—EPHB6—nervous system—Alzheimer's disease	0.000522	0.00433	CbGeAlD
Vandetanib—FLT4—brain—Alzheimer's disease	0.000519	0.00431	CbGeAlD
Vandetanib—RIPK2—brain—Alzheimer's disease	0.000516	0.00428	CbGeAlD
Vandetanib—VEGFA—brain—Alzheimer's disease	0.000514	0.00427	CbGeAlD
Vandetanib—TEK—cerebellum—Alzheimer's disease	0.000514	0.00427	CbGeAlD
Vandetanib—MAP4K5—cerebellum—Alzheimer's disease	0.000514	0.00427	CbGeAlD
Vandetanib—FMO1—brain—Alzheimer's disease	0.000512	0.00425	CbGeAlD
Vandetanib—YES1—nervous system—Alzheimer's disease	0.000504	0.00419	CbGeAlD
Vandetanib—IRAK4—brain—Alzheimer's disease	0.000504	0.00418	CbGeAlD
Vandetanib—EPHB6—central nervous system—Alzheimer's disease	0.000502	0.00417	CbGeAlD
Vandetanib—STK10—nervous system—Alzheimer's disease	0.000499	0.00415	CbGeAlD
Vandetanib—ERBB3—brain—Alzheimer's disease	0.000494	0.0041	CbGeAlD
Vandetanib—EPHB6—cerebellum—Alzheimer's disease	0.000491	0.00408	CbGeAlD
Vandetanib—YES1—central nervous system—Alzheimer's disease	0.000485	0.00403	CbGeAlD
Vandetanib—SRC—nervous system—Alzheimer's disease	0.000485	0.00403	CbGeAlD
Vandetanib—STK10—central nervous system—Alzheimer's disease	0.000481	0.00399	CbGeAlD
Vandetanib—YES1—cerebellum—Alzheimer's disease	0.000474	0.00394	CbGeAlD
Vandetanib—STK10—cerebellum—Alzheimer's disease	0.00047	0.0039	CbGeAlD
Vandetanib—SRC—central nervous system—Alzheimer's disease	0.000467	0.00388	CbGeAlD
Vandetanib—Erlotinib—CYP2D6—Alzheimer's disease	0.000465	0.0936	CrCbGaD
Vandetanib—MKNK1—brain—Alzheimer's disease	0.000464	0.00385	CbGeAlD
Vandetanib—Gastritis—Rivastigmine—Alzheimer's disease	0.000462	0.00196	CcSEcCtD
Vandetanib—Dysphagia—Memantine—Alzheimer's disease	0.000461	0.00196	CcSEcCtD
Vandetanib—Influenza—Memantine—Alzheimer's disease	0.000461	0.00196	CcSEcCtD
Vandetanib—Mental disorder—Galantamine—Alzheimer's disease	0.000459	0.00195	CcSEcCtD
Vandetanib—Weight decreased—Donepezil—Alzheimer's disease	0.000459	0.00195	CcSEcCtD
Vandetanib—FGR—brain—Alzheimer's disease	0.000458	0.0038	CbGeAlD
Vandetanib—RET—brain—Alzheimer's disease	0.000458	0.0038	CbGeAlD
Vandetanib—Hyperglycaemia—Donepezil—Alzheimer's disease	0.000458	0.00195	CcSEcCtD
Vandetanib—Malnutrition—Galantamine—Alzheimer's disease	0.000456	0.00194	CcSEcCtD
Vandetanib—SRC—cerebellum—Alzheimer's disease	0.000456	0.00379	CbGeAlD
Vandetanib—AXL—brain—Alzheimer's disease	0.000456	0.00379	CbGeAlD
Vandetanib—Pneumonia—Donepezil—Alzheimer's disease	0.000455	0.00194	CcSEcCtD
Vandetanib—Bronchospasm—Memantine—Alzheimer's disease	0.000453	0.00193	CcSEcCtD
Vandetanib—Infestation NOS—Donepezil—Alzheimer's disease	0.000453	0.00193	CcSEcCtD
Vandetanib—Infestation—Donepezil—Alzheimer's disease	0.000453	0.00193	CcSEcCtD
Vandetanib—Pancreatitis—Memantine—Alzheimer's disease	0.000452	0.00192	CcSEcCtD
Vandetanib—Depression—Donepezil—Alzheimer's disease	0.000451	0.00192	CcSEcCtD
Vandetanib—Dysphagia—Rivastigmine—Alzheimer's disease	0.000451	0.00192	CcSEcCtD
Vandetanib—Dysgeusia—Galantamine—Alzheimer's disease	0.000447	0.0019	CcSEcCtD
Vandetanib—MAP2K5—nervous system—Alzheimer's disease	0.000446	0.0037	CbGeAlD
Vandetanib—KDR—nervous system—Alzheimer's disease	0.000446	0.0037	CbGeAlD
Vandetanib—Renal failure—Donepezil—Alzheimer's disease	0.000445	0.00189	CcSEcCtD
Vandetanib—ABCC1—telencephalon—Alzheimer's disease	0.000444	0.00369	CbGeAlD
Vandetanib—Bronchospasm—Rivastigmine—Alzheimer's disease	0.000444	0.00189	CcSEcCtD
Vandetanib—Bronchitis—Memantine—Alzheimer's disease	0.000443	0.00189	CcSEcCtD
Vandetanib—FMO3—brain—Alzheimer's disease	0.000442	0.00367	CbGeAlD
Vandetanib—Pancreatitis—Rivastigmine—Alzheimer's disease	0.000442	0.00188	CcSEcCtD
Vandetanib—Conjunctivitis—Donepezil—Alzheimer's disease	0.00044	0.00187	CcSEcCtD
Vandetanib—Urinary tract infection—Donepezil—Alzheimer's disease	0.00044	0.00187	CcSEcCtD
Vandetanib—SLK—brain—Alzheimer's disease	0.000439	0.00365	CbGeAlD
Vandetanib—Muscle spasms—Galantamine—Alzheimer's disease	0.000439	0.00187	CcSEcCtD
Vandetanib—Bronchitis—Rivastigmine—Alzheimer's disease	0.000434	0.00184	CcSEcCtD
Vandetanib—Haematuria—Donepezil—Alzheimer's disease	0.000432	0.00184	CcSEcCtD
Vandetanib—Neutropenia—Memantine—Alzheimer's disease	0.000431	0.00183	CcSEcCtD
Vandetanib—Dysuria—Memantine—Alzheimer's disease	0.000431	0.00183	CcSEcCtD
Vandetanib—Vision blurred—Galantamine—Alzheimer's disease	0.00043	0.00183	CcSEcCtD
Vandetanib—KDR—central nervous system—Alzheimer's disease	0.000429	0.00357	CbGeAlD
Vandetanib—MAP2K5—central nervous system—Alzheimer's disease	0.000429	0.00357	CbGeAlD
Vandetanib—Upper respiratory tract infection—Memantine—Alzheimer's disease	0.000428	0.00182	CcSEcCtD
Vandetanib—Tremor—Galantamine—Alzheimer's disease	0.000428	0.00182	CcSEcCtD
Vandetanib—Epistaxis—Donepezil—Alzheimer's disease	0.000427	0.00182	CcSEcCtD
Vandetanib—FYN—brain—Alzheimer's disease	0.000427	0.00355	CbGeAlD
Vandetanib—Pollakiuria—Memantine—Alzheimer's disease	0.000426	0.00181	CcSEcCtD
Vandetanib—Dysuria—Rivastigmine—Alzheimer's disease	0.000422	0.00179	CcSEcCtD
Vandetanib—KDR—cerebellum—Alzheimer's disease	0.00042	0.00349	CbGeAlD
Vandetanib—MAP2K5—cerebellum—Alzheimer's disease	0.00042	0.00349	CbGeAlD
Vandetanib—Upper respiratory tract infection—Rivastigmine—Alzheimer's disease	0.000419	0.00178	CcSEcCtD
Vandetanib—MAP4K5—brain—Alzheimer's disease	0.000417	0.00346	CbGeAlD
Vandetanib—TEK—brain—Alzheimer's disease	0.000417	0.00346	CbGeAlD
Vandetanib—Weight decreased—Memantine—Alzheimer's disease	0.000417	0.00177	CcSEcCtD
Vandetanib—Pollakiuria—Rivastigmine—Alzheimer's disease	0.000417	0.00177	CcSEcCtD
Vandetanib—Hyperglycaemia—Memantine—Alzheimer's disease	0.000416	0.00177	CcSEcCtD
Vandetanib—Bradycardia—Donepezil—Alzheimer's disease	0.000414	0.00176	CcSEcCtD
Vandetanib—Pneumonia—Memantine—Alzheimer's disease	0.000413	0.00176	CcSEcCtD
Vandetanib—Photosensitivity reaction—Rivastigmine—Alzheimer's disease	0.000412	0.00175	CcSEcCtD
Vandetanib—Infestation NOS—Memantine—Alzheimer's disease	0.000411	0.00175	CcSEcCtD
Vandetanib—Infestation—Memantine—Alzheimer's disease	0.000411	0.00175	CcSEcCtD
Vandetanib—Depression—Memantine—Alzheimer's disease	0.00041	0.00174	CcSEcCtD
Vandetanib—Haemoglobin—Donepezil—Alzheimer's disease	0.000408	0.00174	CcSEcCtD
Vandetanib—Weight decreased—Rivastigmine—Alzheimer's disease	0.000408	0.00174	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Memantine—Alzheimer's disease	0.000407	0.00173	CcSEcCtD
Vandetanib—Hyperglycaemia—Rivastigmine—Alzheimer's disease	0.000407	0.00173	CcSEcCtD
Vandetanib—Haemorrhage—Donepezil—Alzheimer's disease	0.000406	0.00173	CcSEcCtD
Vandetanib—Pneumonia—Rivastigmine—Alzheimer's disease	0.000404	0.00172	CcSEcCtD
Vandetanib—Renal failure—Memantine—Alzheimer's disease	0.000404	0.00172	CcSEcCtD
Vandetanib—Infestation—Rivastigmine—Alzheimer's disease	0.000402	0.00171	CcSEcCtD
Vandetanib—Infestation NOS—Rivastigmine—Alzheimer's disease	0.000402	0.00171	CcSEcCtD
Vandetanib—Urinary tract disorder—Donepezil—Alzheimer's disease	0.000401	0.00171	CcSEcCtD
Vandetanib—Loss of consciousness—Galantamine—Alzheimer's disease	0.000401	0.00171	CcSEcCtD
Vandetanib—Depression—Rivastigmine—Alzheimer's disease	0.000401	0.00171	CcSEcCtD
Vandetanib—Urinary tract infection—Memantine—Alzheimer's disease	0.000399	0.0017	CcSEcCtD
Vandetanib—Conjunctivitis—Memantine—Alzheimer's disease	0.000399	0.0017	CcSEcCtD
Vandetanib—EPHB6—brain—Alzheimer's disease	0.000399	0.00331	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Rivastigmine—Alzheimer's disease	0.000399	0.0017	CcSEcCtD
Vandetanib—Urethral disorder—Donepezil—Alzheimer's disease	0.000398	0.00169	CcSEcCtD
Vandetanib—Cough—Galantamine—Alzheimer's disease	0.000398	0.00169	CcSEcCtD
Vandetanib—Convulsion—Galantamine—Alzheimer's disease	0.000395	0.00168	CcSEcCtD
Vandetanib—Renal failure—Rivastigmine—Alzheimer's disease	0.000395	0.00168	CcSEcCtD
Vandetanib—Hypertension—Galantamine—Alzheimer's disease	0.000394	0.00168	CcSEcCtD
Vandetanib—Haematuria—Memantine—Alzheimer's disease	0.000392	0.00167	CcSEcCtD
Vandetanib—Visual impairment—Donepezil—Alzheimer's disease	0.000392	0.00167	CcSEcCtD
Vandetanib—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.000391	0.00166	CcSEcCtD
Vandetanib—Conjunctivitis—Rivastigmine—Alzheimer's disease	0.000391	0.00166	CcSEcCtD
Vandetanib—Hepatobiliary disease—Memantine—Alzheimer's disease	0.000389	0.00165	CcSEcCtD
Vandetanib—Chest pain—Galantamine—Alzheimer's disease	0.000389	0.00165	CcSEcCtD
Vandetanib—Arthralgia—Galantamine—Alzheimer's disease	0.000389	0.00165	CcSEcCtD
Vandetanib—Epistaxis—Memantine—Alzheimer's disease	0.000388	0.00165	CcSEcCtD
Vandetanib—Anxiety—Galantamine—Alzheimer's disease	0.000387	0.00165	CcSEcCtD
Vandetanib—PDGFRB—nervous system—Alzheimer's disease	0.000386	0.00321	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.000386	0.00164	CcSEcCtD
Vandetanib—Sinusitis—Memantine—Alzheimer's disease	0.000386	0.00164	CcSEcCtD
Vandetanib—YES1—brain—Alzheimer's disease	0.000385	0.0032	CbGeAlD
Vandetanib—Haematuria—Rivastigmine—Alzheimer's disease	0.000383	0.00163	CcSEcCtD
Vandetanib—STK10—brain—Alzheimer's disease	0.000382	0.00317	CbGeAlD
Vandetanib—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.00038	0.00162	CcSEcCtD
Vandetanib—Dry mouth—Galantamine—Alzheimer's disease	0.00038	0.00162	CcSEcCtD
Vandetanib—Epistaxis—Rivastigmine—Alzheimer's disease	0.000379	0.00161	CcSEcCtD
Vandetanib—Sinusitis—Rivastigmine—Alzheimer's disease	0.000377	0.0016	CcSEcCtD
Vandetanib—Bradycardia—Memantine—Alzheimer's disease	0.000376	0.0016	CcSEcCtD
Vandetanib—PDGFRB—central nervous system—Alzheimer's disease	0.000372	0.00309	CbGeAlD
Vandetanib—Haemoglobin—Memantine—Alzheimer's disease	0.000371	0.00158	CcSEcCtD
Vandetanib—SRC—brain—Alzheimer's disease	0.000371	0.00308	CbGeAlD
Vandetanib—Haemorrhage—Memantine—Alzheimer's disease	0.000369	0.00157	CcSEcCtD
Vandetanib—ABCG2—telencephalon—Alzheimer's disease	0.000368	0.00305	CbGeAlD
Vandetanib—Bradycardia—Rivastigmine—Alzheimer's disease	0.000367	0.00156	CcSEcCtD
Vandetanib—Nervous system disorder—Galantamine—Alzheimer's disease	0.000365	0.00155	CcSEcCtD
Vandetanib—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000365	0.00155	CcSEcCtD
Vandetanib—Urinary tract disorder—Memantine—Alzheimer's disease	0.000364	0.00155	CcSEcCtD
Vandetanib—PDGFRB—cerebellum—Alzheimer's disease	0.000363	0.00302	CbGeAlD
Vandetanib—Arrhythmia—Donepezil—Alzheimer's disease	0.000363	0.00154	CcSEcCtD
Vandetanib—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000363	0.00154	CcSEcCtD
Vandetanib—ORM1—nervous system—Alzheimer's disease	0.000362	0.00301	CbGeAlD
Vandetanib—Skin disorder—Galantamine—Alzheimer's disease	0.000362	0.00154	CcSEcCtD
Vandetanib—Urethral disorder—Memantine—Alzheimer's disease	0.000362	0.00154	CcSEcCtD
Vandetanib—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000361	0.00154	CcSEcCtD
Vandetanib—Alopecia—Donepezil—Alzheimer's disease	0.000359	0.00153	CcSEcCtD
Vandetanib—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000356	0.00152	CcSEcCtD
Vandetanib—Mental disorder—Donepezil—Alzheimer's disease	0.000356	0.00151	CcSEcCtD
Vandetanib—Visual impairment—Memantine—Alzheimer's disease	0.000356	0.00151	CcSEcCtD
Vandetanib—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000354	0.0015	CcSEcCtD
Vandetanib—Malnutrition—Donepezil—Alzheimer's disease	0.000354	0.0015	CcSEcCtD
Vandetanib—Erythema multiforme—Memantine—Alzheimer's disease	0.000349	0.00148	CcSEcCtD
Vandetanib—ORM1—central nervous system—Alzheimer's disease	0.000349	0.0029	CbGeAlD
Vandetanib—Visual impairment—Rivastigmine—Alzheimer's disease	0.000348	0.00148	CcSEcCtD
Vandetanib—Dysgeusia—Donepezil—Alzheimer's disease	0.000346	0.00147	CcSEcCtD
Vandetanib—Eye disorder—Memantine—Alzheimer's disease	0.000345	0.00147	CcSEcCtD
Vandetanib—ABL1—nervous system—Alzheimer's disease	0.000344	0.00286	CbGeAlD
Vandetanib—Cardiac disorder—Memantine—Alzheimer's disease	0.000342	0.00146	CcSEcCtD
Vandetanib—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000341	0.00145	CcSEcCtD
Vandetanib—MAP2K5—brain—Alzheimer's disease	0.000341	0.00283	CbGeAlD
Vandetanib—KDR—brain—Alzheimer's disease	0.000341	0.00283	CbGeAlD
Vandetanib—Muscle spasms—Donepezil—Alzheimer's disease	0.00034	0.00145	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000339	0.00144	CcSEcCtD
Vandetanib—Eye disorder—Rivastigmine—Alzheimer's disease	0.000337	0.00143	CcSEcCtD
Vandetanib—Insomnia—Galantamine—Alzheimer's disease	0.000337	0.00143	CcSEcCtD
Vandetanib—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000335	0.00142	CcSEcCtD
Vandetanib—Angiopathy—Memantine—Alzheimer's disease	0.000335	0.00142	CcSEcCtD
Vandetanib—Paraesthesia—Galantamine—Alzheimer's disease	0.000334	0.00142	CcSEcCtD
Vandetanib—Vision blurred—Donepezil—Alzheimer's disease	0.000333	0.00142	CcSEcCtD
Vandetanib—Mediastinal disorder—Memantine—Alzheimer's disease	0.000333	0.00141	CcSEcCtD
Vandetanib—Tremor—Donepezil—Alzheimer's disease	0.000331	0.00141	CcSEcCtD
Vandetanib—ABL1—central nervous system—Alzheimer's disease	0.000331	0.00275	CbGeAlD
Vandetanib—Arrhythmia—Memantine—Alzheimer's disease	0.00033	0.0014	CcSEcCtD
Vandetanib—Dyspepsia—Galantamine—Alzheimer's disease	0.000328	0.00139	CcSEcCtD
Vandetanib—Angiopathy—Rivastigmine—Alzheimer's disease	0.000327	0.00139	CcSEcCtD
Vandetanib—Alopecia—Memantine—Alzheimer's disease	0.000326	0.00139	CcSEcCtD
Vandetanib—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000325	0.00138	CcSEcCtD
Vandetanib—Decreased appetite—Galantamine—Alzheimer's disease	0.000324	0.00138	CcSEcCtD
Vandetanib—ABL1—cerebellum—Alzheimer's disease	0.000324	0.00269	CbGeAlD
Vandetanib—Mental disorder—Memantine—Alzheimer's disease	0.000323	0.00137	CcSEcCtD
Vandetanib—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000322	0.00137	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000322	0.00137	CcSEcCtD
Vandetanib—Malnutrition—Memantine—Alzheimer's disease	0.000321	0.00137	CcSEcCtD
Vandetanib—Fatigue—Galantamine—Alzheimer's disease	0.000321	0.00137	CcSEcCtD
Vandetanib—Alopecia—Rivastigmine—Alzheimer's disease	0.000319	0.00136	CcSEcCtD
Vandetanib—Constipation—Galantamine—Alzheimer's disease	0.000319	0.00136	CcSEcCtD
Vandetanib—Mental disorder—Rivastigmine—Alzheimer's disease	0.000316	0.00135	CcSEcCtD
Vandetanib—Dysgeusia—Memantine—Alzheimer's disease	0.000315	0.00134	CcSEcCtD
Vandetanib—Malnutrition—Rivastigmine—Alzheimer's disease	0.000314	0.00134	CcSEcCtD
Vandetanib—Loss of consciousness—Donepezil—Alzheimer's disease	0.000311	0.00132	CcSEcCtD
Vandetanib—Cough—Donepezil—Alzheimer's disease	0.000309	0.00131	CcSEcCtD
Vandetanib—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000308	0.00131	CcSEcCtD
Vandetanib—Convulsion—Donepezil—Alzheimer's disease	0.000306	0.0013	CcSEcCtD
Vandetanib—Hypertension—Donepezil—Alzheimer's disease	0.000305	0.0013	CcSEcCtD
Vandetanib—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000305	0.0013	CcSEcCtD
Vandetanib—Vision blurred—Memantine—Alzheimer's disease	0.000303	0.00129	CcSEcCtD
Vandetanib—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000302	0.00128	CcSEcCtD
Vandetanib—Chest pain—Donepezil—Alzheimer's disease	0.000301	0.00128	CcSEcCtD
Vandetanib—Arthralgia—Donepezil—Alzheimer's disease	0.000301	0.00128	CcSEcCtD
Vandetanib—Tremor—Memantine—Alzheimer's disease	0.000301	0.00128	CcSEcCtD
Vandetanib—Anxiety—Donepezil—Alzheimer's disease	0.0003	0.00128	CcSEcCtD
Vandetanib—Vision blurred—Rivastigmine—Alzheimer's disease	0.000296	0.00126	CcSEcCtD
Vandetanib—PDGFRB—brain—Alzheimer's disease	0.000295	0.00245	CbGeAlD
Vandetanib—Dry mouth—Donepezil—Alzheimer's disease	0.000295	0.00125	CcSEcCtD
Vandetanib—Abdominal pain—Galantamine—Alzheimer's disease	0.000294	0.00125	CcSEcCtD
Vandetanib—Body temperature increased—Galantamine—Alzheimer's disease	0.000294	0.00125	CcSEcCtD
Vandetanib—Tremor—Rivastigmine—Alzheimer's disease	0.000294	0.00125	CcSEcCtD
Vandetanib—Gefitinib—CYP2D6—Alzheimer's disease	0.000291	0.0586	CrCbGaD
Vandetanib—Oedema—Donepezil—Alzheimer's disease	0.000289	0.00123	CcSEcCtD
Vandetanib—Infection—Donepezil—Alzheimer's disease	0.000287	0.00122	CcSEcCtD
Vandetanib—Nervous system disorder—Donepezil—Alzheimer's disease	0.000283	0.0012	CcSEcCtD
Vandetanib—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000283	0.0012	CcSEcCtD
Vandetanib—Loss of consciousness—Memantine—Alzheimer's disease	0.000282	0.0012	CcSEcCtD
Vandetanib—Cough—Memantine—Alzheimer's disease	0.00028	0.00119	CcSEcCtD
Vandetanib—Convulsion—Memantine—Alzheimer's disease	0.000278	0.00118	CcSEcCtD
Vandetanib—Hypertension—Memantine—Alzheimer's disease	0.000277	0.00118	CcSEcCtD
Vandetanib—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000276	0.00117	CcSEcCtD
Vandetanib—Cough—Rivastigmine—Alzheimer's disease	0.000274	0.00117	CcSEcCtD
Vandetanib—Chest pain—Memantine—Alzheimer's disease	0.000273	0.00116	CcSEcCtD
Vandetanib—Arthralgia—Memantine—Alzheimer's disease	0.000273	0.00116	CcSEcCtD
Vandetanib—Anxiety—Memantine—Alzheimer's disease	0.000272	0.00116	CcSEcCtD
Vandetanib—Convulsion—Rivastigmine—Alzheimer's disease	0.000272	0.00116	CcSEcCtD
Vandetanib—Hypertension—Rivastigmine—Alzheimer's disease	0.000271	0.00115	CcSEcCtD
Vandetanib—Chest pain—Rivastigmine—Alzheimer's disease	0.000267	0.00114	CcSEcCtD
Vandetanib—Arthralgia—Rivastigmine—Alzheimer's disease	0.000267	0.00114	CcSEcCtD
Vandetanib—Dry mouth—Memantine—Alzheimer's disease	0.000267	0.00114	CcSEcCtD
Vandetanib—Asthenia—Galantamine—Alzheimer's disease	0.000267	0.00114	CcSEcCtD
Vandetanib—Anxiety—Rivastigmine—Alzheimer's disease	0.000267	0.00113	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000266	0.00113	CcSEcCtD
Vandetanib—ABL1—brain—Alzheimer's disease	0.000263	0.00218	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000263	0.00112	CcSEcCtD
Vandetanib—Oedema—Memantine—Alzheimer's disease	0.000262	0.00111	CcSEcCtD
Vandetanib—Dry mouth—Rivastigmine—Alzheimer's disease	0.000262	0.00111	CcSEcCtD
Vandetanib—Insomnia—Donepezil—Alzheimer's disease	0.000261	0.00111	CcSEcCtD
Vandetanib—Infection—Memantine—Alzheimer's disease	0.00026	0.00111	CcSEcCtD
Vandetanib—Paraesthesia—Donepezil—Alzheimer's disease	0.000259	0.0011	CcSEcCtD
Vandetanib—Dyspnoea—Donepezil—Alzheimer's disease	0.000257	0.00109	CcSEcCtD
Vandetanib—Nervous system disorder—Memantine—Alzheimer's disease	0.000257	0.00109	CcSEcCtD
Vandetanib—Thrombocytopenia—Memantine—Alzheimer's disease	0.000257	0.00109	CcSEcCtD
Vandetanib—Oedema—Rivastigmine—Alzheimer's disease	0.000256	0.00109	CcSEcCtD
Vandetanib—Diarrhoea—Galantamine—Alzheimer's disease	0.000255	0.00108	CcSEcCtD
Vandetanib—Infection—Rivastigmine—Alzheimer's disease	0.000255	0.00108	CcSEcCtD
Vandetanib—Skin disorder—Memantine—Alzheimer's disease	0.000255	0.00108	CcSEcCtD
Vandetanib—Dyspepsia—Donepezil—Alzheimer's disease	0.000254	0.00108	CcSEcCtD
Vandetanib—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000251	0.00107	CcSEcCtD
Vandetanib—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000251	0.00107	CcSEcCtD
Vandetanib—Decreased appetite—Donepezil—Alzheimer's disease	0.000251	0.00107	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000249	0.00106	CcSEcCtD
Vandetanib—Skin disorder—Rivastigmine—Alzheimer's disease	0.000249	0.00106	CcSEcCtD
Vandetanib—Fatigue—Donepezil—Alzheimer's disease	0.000249	0.00106	CcSEcCtD
Vandetanib—Constipation—Donepezil—Alzheimer's disease	0.000247	0.00105	CcSEcCtD
Vandetanib—Pain—Donepezil—Alzheimer's disease	0.000247	0.00105	CcSEcCtD
Vandetanib—ABCC1—cerebellum—Alzheimer's disease	0.000247	0.00205	CbGeAlD
Vandetanib—Dizziness—Galantamine—Alzheimer's disease	0.000246	0.00105	CcSEcCtD
Vandetanib—ALB—brain—Alzheimer's disease	0.000243	0.00202	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000239	0.00102	CcSEcCtD
Vandetanib—Insomnia—Memantine—Alzheimer's disease	0.000237	0.00101	CcSEcCtD
Vandetanib—Vomiting—Galantamine—Alzheimer's disease	0.000237	0.00101	CcSEcCtD
Vandetanib—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000236	0.001	CcSEcCtD
Vandetanib—Paraesthesia—Memantine—Alzheimer's disease	0.000235	0.001	CcSEcCtD
Vandetanib—Rash—Galantamine—Alzheimer's disease	0.000235	0.000999	CcSEcCtD
Vandetanib—Dermatitis—Galantamine—Alzheimer's disease	0.000235	0.000998	CcSEcCtD
Vandetanib—Dyspnoea—Memantine—Alzheimer's disease	0.000234	0.000994	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000234	0.000994	CcSEcCtD
Vandetanib—Headache—Galantamine—Alzheimer's disease	0.000233	0.000993	CcSEcCtD
Vandetanib—Insomnia—Rivastigmine—Alzheimer's disease	0.000232	0.000987	CcSEcCtD
Vandetanib—Dyspepsia—Memantine—Alzheimer's disease	0.000231	0.000981	CcSEcCtD
Vandetanib—Paraesthesia—Rivastigmine—Alzheimer's disease	0.00023	0.000979	CcSEcCtD
Vandetanib—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000229	0.000972	CcSEcCtD
Vandetanib—Abdominal pain—Donepezil—Alzheimer's disease	0.000228	0.000971	CcSEcCtD
Vandetanib—Body temperature increased—Donepezil—Alzheimer's disease	0.000228	0.000971	CcSEcCtD
Vandetanib—Decreased appetite—Memantine—Alzheimer's disease	0.000228	0.000969	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000226	0.000963	CcSEcCtD
Vandetanib—Fatigue—Memantine—Alzheimer's disease	0.000226	0.000961	CcSEcCtD
Vandetanib—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000226	0.00096	CcSEcCtD
Vandetanib—Pain—Memantine—Alzheimer's disease	0.000224	0.000953	CcSEcCtD
Vandetanib—Constipation—Memantine—Alzheimer's disease	0.000224	0.000953	CcSEcCtD
Vandetanib—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000223	0.000948	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000221	0.000942	CcSEcCtD
Vandetanib—Nausea—Galantamine—Alzheimer's disease	0.000221	0.000941	CcSEcCtD
Vandetanib—Fatigue—Rivastigmine—Alzheimer's disease	0.000221	0.00094	CcSEcCtD
Vandetanib—Constipation—Rivastigmine—Alzheimer's disease	0.000219	0.000933	CcSEcCtD
Vandetanib—Pain—Rivastigmine—Alzheimer's disease	0.000219	0.000933	CcSEcCtD
Vandetanib—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000214	0.000912	CcSEcCtD
Vandetanib—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.00021	0.000892	CcSEcCtD
Vandetanib—Abdominal pain—Memantine—Alzheimer's disease	0.000207	0.000881	CcSEcCtD
Vandetanib—Body temperature increased—Memantine—Alzheimer's disease	0.000207	0.000881	CcSEcCtD
Vandetanib—Asthenia—Donepezil—Alzheimer's disease	0.000207	0.000881	CcSEcCtD
Vandetanib—Pruritus—Donepezil—Alzheimer's disease	0.000204	0.000869	CcSEcCtD
Vandetanib—ABCG2—cerebellum—Alzheimer's disease	0.000204	0.0017	CbGeAlD
Vandetanib—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000203	0.000862	CcSEcCtD
Vandetanib—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000203	0.000862	CcSEcCtD
Vandetanib—ABCC1—brain—Alzheimer's disease	0.0002	0.00166	CbGeAlD
Vandetanib—Diarrhoea—Donepezil—Alzheimer's disease	0.000198	0.00084	CcSEcCtD
Vandetanib—Dizziness—Donepezil—Alzheimer's disease	0.000191	0.000812	CcSEcCtD
Vandetanib—Asthenia—Memantine—Alzheimer's disease	0.000188	0.0008	CcSEcCtD
Vandetanib—Pruritus—Memantine—Alzheimer's disease	0.000185	0.000789	CcSEcCtD
Vandetanib—Asthenia—Rivastigmine—Alzheimer's disease	0.000184	0.000783	CcSEcCtD
Vandetanib—Vomiting—Donepezil—Alzheimer's disease	0.000184	0.000781	CcSEcCtD
Vandetanib—Rash—Donepezil—Alzheimer's disease	0.000182	0.000774	CcSEcCtD
Vandetanib—Dermatitis—Donepezil—Alzheimer's disease	0.000182	0.000774	CcSEcCtD
Vandetanib—Pruritus—Rivastigmine—Alzheimer's disease	0.000181	0.000772	CcSEcCtD
Vandetanib—Headache—Donepezil—Alzheimer's disease	0.000181	0.000769	CcSEcCtD
Vandetanib—Diarrhoea—Memantine—Alzheimer's disease	0.000179	0.000763	CcSEcCtD
Vandetanib—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000175	0.000746	CcSEcCtD
Vandetanib—Dizziness—Memantine—Alzheimer's disease	0.000173	0.000737	CcSEcCtD
Vandetanib—Nausea—Donepezil—Alzheimer's disease	0.000171	0.000729	CcSEcCtD
Vandetanib—Dizziness—Rivastigmine—Alzheimer's disease	0.00017	0.000721	CcSEcCtD
Vandetanib—Vomiting—Memantine—Alzheimer's disease	0.000167	0.000709	CcSEcCtD
Vandetanib—ABCG2—brain—Alzheimer's disease	0.000166	0.00138	CbGeAlD
Vandetanib—Rash—Memantine—Alzheimer's disease	0.000165	0.000703	CcSEcCtD
Vandetanib—Dermatitis—Memantine—Alzheimer's disease	0.000165	0.000702	CcSEcCtD
Vandetanib—Headache—Memantine—Alzheimer's disease	0.000164	0.000699	CcSEcCtD
Vandetanib—Vomiting—Rivastigmine—Alzheimer's disease	0.000163	0.000694	CcSEcCtD
Vandetanib—Rash—Rivastigmine—Alzheimer's disease	0.000162	0.000688	CcSEcCtD
Vandetanib—Dermatitis—Rivastigmine—Alzheimer's disease	0.000162	0.000687	CcSEcCtD
Vandetanib—Headache—Rivastigmine—Alzheimer's disease	0.000161	0.000683	CcSEcCtD
Vandetanib—Nausea—Memantine—Alzheimer's disease	0.000156	0.000662	CcSEcCtD
Vandetanib—Nausea—Rivastigmine—Alzheimer's disease	0.000152	0.000648	CcSEcCtD
Vandetanib—CYP3A4—nervous system—Alzheimer's disease	0.000151	0.00126	CbGeAlD
Vandetanib—CYP3A4—central nervous system—Alzheimer's disease	0.000146	0.00121	CbGeAlD
Vandetanib—LCK—Disease—NOS3—Alzheimer's disease	2.43e-06	9.65e-06	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—Alzheimer's disease	2.42e-06	9.6e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—INS—Alzheimer's disease	2.42e-06	9.6e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—GSK3B—Alzheimer's disease	2.4e-06	9.53e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LPL—Alzheimer's disease	2.4e-06	9.52e-06	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—Alzheimer's disease	2.39e-06	9.51e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CREB1—Alzheimer's disease	2.38e-06	9.45e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TGFB1—Alzheimer's disease	2.38e-06	9.45e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCL2—Alzheimer's disease	2.38e-06	9.45e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MEF2C—Alzheimer's disease	2.38e-06	9.44e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—Alzheimer's disease	2.37e-06	9.41e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—INS—Alzheimer's disease	2.37e-06	9.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CALM1—Alzheimer's disease	2.36e-06	9.39e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CASP3—Alzheimer's disease	2.36e-06	9.38e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—GSK3B—Alzheimer's disease	2.36e-06	9.38e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—LEP—Alzheimer's disease	2.35e-06	9.36e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APOE—Alzheimer's disease	2.35e-06	9.36e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CREB1—Alzheimer's disease	2.34e-06	9.3e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1—Alzheimer's disease	2.34e-06	9.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—Alzheimer's disease	2.33e-06	9.28e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CAV1—Alzheimer's disease	2.33e-06	9.27e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PRKCG—Alzheimer's disease	2.33e-06	9.26e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—INS—Alzheimer's disease	2.33e-06	9.25e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCL2—Alzheimer's disease	2.33e-06	9.25e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—Alzheimer's disease	2.32e-06	9.23e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—Alzheimer's disease	2.31e-06	9.17e-06	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—Alzheimer's disease	2.31e-06	9.16e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—Alzheimer's disease	2.3e-06	9.16e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL2—Alzheimer's disease	2.29e-06	9.1e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PPARG—Alzheimer's disease	2.29e-06	9.1e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1—Alzheimer's disease	2.29e-06	9.09e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—Alzheimer's disease	2.28e-06	9.07e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CALM1—Alzheimer's disease	2.28e-06	9.05e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NGF—Alzheimer's disease	2.27e-06	9.02e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APOE—Alzheimer's disease	2.27e-06	9.02e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LEP—Alzheimer's disease	2.27e-06	9.02e-06	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—Alzheimer's disease	2.26e-06	8.96e-06	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—Alzheimer's disease	2.25e-06	8.96e-06	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—Alzheimer's disease	2.25e-06	8.95e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1—Alzheimer's disease	2.25e-06	8.95e-06	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—Alzheimer's disease	2.25e-06	8.94e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CAV1—Alzheimer's disease	2.25e-06	8.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ESR1—Alzheimer's disease	2.25e-06	8.93e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK8—Alzheimer's disease	2.25e-06	8.93e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—INS—Alzheimer's disease	2.25e-06	8.93e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—BCL2—Alzheimer's disease	2.24e-06	8.91e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—NOS3—Alzheimer's disease	2.24e-06	8.89e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—Alzheimer's disease	2.24e-06	8.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—F2—Alzheimer's disease	2.22e-06	8.82e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—Alzheimer's disease	2.22e-06	8.82e-06	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—Alzheimer's disease	2.22e-06	8.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCR5—Alzheimer's disease	2.21e-06	8.77e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TGFB1—Alzheimer's disease	2.17e-06	8.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOTCH1—Alzheimer's disease	2.17e-06	8.64e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK8—Alzheimer's disease	2.17e-06	8.63e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ESR1—Alzheimer's disease	2.17e-06	8.61e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR2A—Alzheimer's disease	2.16e-06	8.59e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—Alzheimer's disease	2.16e-06	8.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CHAT—Alzheimer's disease	2.16e-06	8.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TPI1—Alzheimer's disease	2.16e-06	8.56e-06	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—Alzheimer's disease	2.15e-06	8.56e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS3—Alzheimer's disease	2.15e-06	8.54e-06	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—Alzheimer's disease	2.14e-06	8.52e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—F2—Alzheimer's disease	2.14e-06	8.5e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK8—Alzheimer's disease	2.13e-06	8.46e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARGC1A—Alzheimer's disease	2.13e-06	8.45e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TGFB1—Alzheimer's disease	2.12e-06	8.42e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOS3—Alzheimer's disease	2.12e-06	8.42e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HMOX1—Alzheimer's disease	2.12e-06	8.41e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TGFB1—Alzheimer's disease	2.1e-06	8.33e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOTCH1—Alzheimer's disease	2.09e-06	8.32e-06	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—Alzheimer's disease	2.08e-06	8.27e-06	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—Alzheimer's disease	2.08e-06	8.27e-06	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—Alzheimer's disease	2.08e-06	8.25e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—Alzheimer's disease	2.07e-06	8.24e-06	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—Alzheimer's disease	2.07e-06	8.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MAOB—Alzheimer's disease	2.07e-06	8.21e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK8—Alzheimer's disease	2.05e-06	8.15e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—Alzheimer's disease	2.05e-06	8.14e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—Alzheimer's disease	2.04e-06	8.11e-06	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—Alzheimer's disease	2.04e-06	8.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—GSK3B—Alzheimer's disease	2.04e-06	8.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CREB1—Alzheimer's disease	2.02e-06	8.04e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CALM1—Alzheimer's disease	2.02e-06	8.01e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—INS—Alzheimer's disease	2.01e-06	7.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—Alzheimer's disease	2.01e-06	7.98e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—Alzheimer's disease	2.01e-06	7.98e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—Alzheimer's disease	2e-06	7.96e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—Alzheimer's disease	2e-06	7.95e-06	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—Alzheimer's disease	1.99e-06	7.92e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—Alzheimer's disease	1.99e-06	7.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CAV1—Alzheimer's disease	1.99e-06	7.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	1.99e-06	7.9e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—Alzheimer's disease	1.98e-06	7.88e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—Alzheimer's disease	1.98e-06	7.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—Alzheimer's disease	1.98e-06	7.87e-06	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—Alzheimer's disease	1.98e-06	7.86e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—Alzheimer's disease	1.97e-06	7.83e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—Alzheimer's disease	1.97e-06	7.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GSK3B—Alzheimer's disease	1.97e-06	7.81e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—Alzheimer's disease	1.96e-06	7.78e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CREB1—Alzheimer's disease	1.95e-06	7.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—Alzheimer's disease	1.95e-06	7.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—INS—Alzheimer's disease	1.94e-06	7.7e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LPL—Alzheimer's disease	1.94e-06	7.69e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—Alzheimer's disease	1.93e-06	7.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—A2M—Alzheimer's disease	1.92e-06	7.63e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ESR1—Alzheimer's disease	1.92e-06	7.62e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—Alzheimer's disease	1.91e-06	7.58e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—Alzheimer's disease	1.9e-06	7.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—F2—Alzheimer's disease	1.89e-06	7.53e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—Alzheimer's disease	1.88e-06	7.45e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOTCH1—Alzheimer's disease	1.85e-06	7.37e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—Alzheimer's disease	1.84e-06	7.31e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—Alzheimer's disease	1.84e-06	7.3e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK8—Alzheimer's disease	1.82e-06	7.22e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—Alzheimer's disease	1.8e-06	7.16e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—Alzheimer's disease	1.8e-06	7.15e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—Alzheimer's disease	1.79e-06	7.12e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—Alzheimer's disease	1.79e-06	7.11e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—Alzheimer's disease	1.77e-06	7.02e-06	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—Alzheimer's disease	1.76e-06	7.01e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—Alzheimer's disease	1.76e-06	7.01e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—Alzheimer's disease	1.76e-06	7e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—Alzheimer's disease	1.74e-06	6.93e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—Alzheimer's disease	1.74e-06	6.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GSK3B—Alzheimer's disease	1.74e-06	6.91e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—Alzheimer's disease	1.73e-06	6.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CREB1—Alzheimer's disease	1.73e-06	6.86e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—Alzheimer's disease	1.73e-06	6.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—Alzheimer's disease	1.72e-06	6.82e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—Alzheimer's disease	1.7e-06	6.76e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—Alzheimer's disease	1.69e-06	6.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ACHE—Alzheimer's disease	1.67e-06	6.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—Alzheimer's disease	1.67e-06	6.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—Alzheimer's disease	1.66e-06	6.6e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—Alzheimer's disease	1.65e-06	6.57e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—Alzheimer's disease	1.65e-06	6.57e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	1.65e-06	6.56e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—Alzheimer's disease	1.64e-06	6.51e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—Alzheimer's disease	1.63e-06	6.49e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—Alzheimer's disease	1.63e-06	6.48e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CALM1—Alzheimer's disease	1.63e-06	6.47e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—Alzheimer's disease	1.62e-06	6.45e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—Alzheimer's disease	1.62e-06	6.43e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAV1—Alzheimer's disease	1.61e-06	6.39e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—Alzheimer's disease	1.61e-06	6.38e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—Alzheimer's disease	1.6e-06	6.35e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—Alzheimer's disease	1.6e-06	6.34e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—Alzheimer's disease	1.59e-06	6.33e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—Alzheimer's disease	1.59e-06	6.32e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—Alzheimer's disease	1.58e-06	6.27e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—Alzheimer's disease	1.57e-06	6.25e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—Alzheimer's disease	1.57e-06	6.23e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO1—Alzheimer's disease	1.57e-06	6.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	1.57e-06	6.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	1.54e-06	6.1e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—Alzheimer's disease	1.53e-06	6.06e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—Alzheimer's disease	1.51e-06	6.02e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—Alzheimer's disease	1.51e-06	6.01e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—Alzheimer's disease	1.51e-06	5.99e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—Alzheimer's disease	1.51e-06	5.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—Alzheimer's disease	1.51e-06	5.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—Alzheimer's disease	1.5e-06	5.95e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—Alzheimer's disease	1.49e-06	5.94e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—Alzheimer's disease	1.49e-06	5.91e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—Alzheimer's disease	1.47e-06	5.86e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—Alzheimer's disease	1.47e-06	5.85e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—Alzheimer's disease	1.47e-06	5.85e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—Alzheimer's disease	1.47e-06	5.83e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—Alzheimer's disease	1.46e-06	5.79e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BCHE—Alzheimer's disease	1.46e-06	5.78e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—Alzheimer's disease	1.45e-06	5.77e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—Alzheimer's disease	1.45e-06	5.77e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—Alzheimer's disease	1.44e-06	5.74e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—Alzheimer's disease	1.43e-06	5.7e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—Alzheimer's disease	1.42e-06	5.65e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—Alzheimer's disease	1.41e-06	5.62e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—Alzheimer's disease	1.4e-06	5.57e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—Alzheimer's disease	1.39e-06	5.53e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—Alzheimer's disease	1.39e-06	5.51e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—Alzheimer's disease	1.39e-06	5.51e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—Alzheimer's disease	1.38e-06	5.48e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—Alzheimer's disease	1.38e-06	5.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	1.37e-06	5.46e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—Alzheimer's disease	1.37e-06	5.46e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—Alzheimer's disease	1.37e-06	5.45e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—Alzheimer's disease	1.36e-06	5.4e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—Alzheimer's disease	1.35e-06	5.37e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—Alzheimer's disease	1.34e-06	5.33e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—Alzheimer's disease	1.33e-06	5.29e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	1.33e-06	5.29e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—Alzheimer's disease	1.33e-06	5.27e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—Alzheimer's disease	1.32e-06	5.26e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—Alzheimer's disease	1.31e-06	5.21e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—Alzheimer's disease	1.28e-06	5.08e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—Alzheimer's disease	1.28e-06	5.08e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—Alzheimer's disease	1.27e-06	5.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—Alzheimer's disease	1.26e-06	4.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—Alzheimer's disease	1.25e-06	4.98e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—Alzheimer's disease	1.23e-06	4.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—Alzheimer's disease	1.22e-06	4.87e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—Alzheimer's disease	1.22e-06	4.83e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—Alzheimer's disease	1.21e-06	4.81e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—Alzheimer's disease	1.21e-06	4.8e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—Alzheimer's disease	1.17e-06	4.67e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—Alzheimer's disease	1.17e-06	4.64e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—Alzheimer's disease	1.16e-06	4.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—Alzheimer's disease	1.16e-06	4.6e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—Alzheimer's disease	1.15e-06	4.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	1.15e-06	4.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	1.14e-06	4.54e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—Alzheimer's disease	1.13e-06	4.49e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—Alzheimer's disease	1.12e-06	4.47e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—Alzheimer's disease	1.12e-06	4.43e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—Alzheimer's disease	1.11e-06	4.42e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—Alzheimer's disease	1.11e-06	4.42e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—Alzheimer's disease	1.08e-06	4.31e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—Alzheimer's disease	1.07e-06	4.26e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—Alzheimer's disease	1.07e-06	4.25e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—Alzheimer's disease	1.06e-06	4.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—Alzheimer's disease	1.04e-06	4.15e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—Alzheimer's disease	1.03e-06	4.11e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—Alzheimer's disease	1.03e-06	4.09e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—Alzheimer's disease	1.02e-06	4.04e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—Alzheimer's disease	9.95e-07	3.95e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—Alzheimer's disease	9.88e-07	3.93e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—Alzheimer's disease	9.74e-07	3.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—Alzheimer's disease	9.6e-07	3.82e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—Alzheimer's disease	9.53e-07	3.79e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	9.41e-07	3.74e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—Alzheimer's disease	9.39e-07	3.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—Alzheimer's disease	9.26e-07	3.68e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—Alzheimer's disease	9.05e-07	3.6e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—Alzheimer's disease	8.79e-07	3.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CALM1—Alzheimer's disease	8.79e-07	3.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—Alzheimer's disease	8.76e-07	3.48e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—Alzheimer's disease	8.68e-07	3.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—Alzheimer's disease	8.47e-07	3.37e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—Alzheimer's disease	8.19e-07	3.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—Alzheimer's disease	8.11e-07	3.22e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—Alzheimer's disease	7.82e-07	3.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—Alzheimer's disease	7.63e-07	3.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—Alzheimer's disease	7.5e-07	2.98e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—Alzheimer's disease	7.48e-07	2.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—Alzheimer's disease	6.92e-07	2.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—Alzheimer's disease	6.56e-07	2.61e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	6e-07	2.38e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—Alzheimer's disease	5.59e-07	2.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—Alzheimer's disease	3.02e-07	1.2e-06	CbGpPWpGaD
